Tiecheng “Alex” Qiao is the co-Founder, President & CEO of Ablaze Pharma. Dr. Qiao has over 20 years of experience as an entrepreneur, business leader and technology innovator in the life sciences, biopharmaceutical and high-tech industries.

Prior to Ablaze Pharma, he helped the acquisition of Ambrx led by Fosun Pharma, Hopu, Wuxi and Everbright, and was appointed CEO of the Company upon the completion of the acquisition. During his tenure at Ambrx, he re-built the management team and guided the Company to become a clinical stage biopharmaceutical company with a focus on developing first-in-class and best-in-class antibody drug conjugates to treat cancer.  Prior to Ambrx, he co-founded and was CEO of NajingTech from 2008 to 2012. NajingTech is an innovative materials Company focused on Quantum Dots based product development and commercialization with operations in both U.S. and China.  Prior to NajingTech, Dr. Qiao co-founded and was president of G3 Technology Innovations, which developed nanomaterials for the contract textile industry from 2006 to 2009.  G3 was acquired by private firm BigSky in 2009. Prior to his entrepreneurial career, Dr. Qiao worked at Eastman Kodak Company's Health Group (now Carestream Health) from 1997 to 2006, where he conceived and led the development of biochips, rare cell separation, and molecular imaging platforms.  

A prolific inventor with 27 issued U.S. patents, Dr. Qiao earned his Ph.D. in chemistry from the University of Rochester and completed his postdoctoral training in biochemistry at the Massachusetts Institute of Technology.  

Alan Xu is the co-Founder and COO of Ablaze Pharma. Mr. Xu has more than 25 years of combined experience in investment, business operation, business development, corporate development, finance, and supply chain management.

Prior to Ablaze Pharma, he was Executive Director of CMH Healthcare Fund, a co-GP fund of HOPU Investment, Mitsui and China Resources and he was Senior Advisor of HOPU Investments since 2018, helped fundraising for HOPU Healthcare Funds and HOPU's investment to HPGC, Lyndra, IMab and Ambrx. Prior to it, Mr. Xu was VP, GM-China and Board Secretary of Ambrx from 2015. From 2006 to 2014, he worked at China NT Pharma Group, where he had increasing management responsibilities as VP and GM of Business Development, GM of Vaccines BU, GM of Pharma Commercial. Prior to it, Mr. Xu was Head of Finance and Commercial of Dr. Reddy's China from 2003 to 2006. Previously, Mr. Xu was National Commercial and Sales Administration Manager at Bayer China from 1998 to 2003 and Associate Sales Manager of Merck Sharp & Dohme China from 1995 to 1998.

Alan received EMBA degree and BS degree in pharmaceutical from Fudan University.

Dr. Jin Wang is the CMO of Ablaze Pharma. She has more than 10 years’ experience in the clinical development industry and 5 years’ experience as an oncology physician.

Prior to Ablaze Pharma, Dr. Wang was the Executive Director, Clinical Development at BeiGene from 2018 to 2022, where she led the clinical development of innovative anti-cancer drugs from strategy, implementation to registration for both BeiGene’s assets and in-licensing assets. In 2017, she was the Medical Head of Biotech Delivery Unit at IQVIA Greater China, where she provided strategic consultation to China biotech companies and oversaw multiple clinical trials. From 2012 to 2017, Dr. Wang was responsible for oncology drug development and medical affairs as the Clinical Research Physician of Eli Lilly China. Dr. Wang has extensive experience working on oncology drug development from strategy, design, delivery to interpretation, covering monotherapy and combination therapy in Phase 1-3 trials and ranging from small molecules, biologicals to ADC.

Prior to industry, Dr. Wang was served as Attending physician and instructor, Department of Medical Oncology, Shanghai Changzheng Hospital for about 5 years. She received her Ph.D. from the Second Military Medical University and MD from the Fourth Military Medical University.

Dr. Wen has more than 20 years of CMC experiences, especially in innovative drugs. Prior to Ablaze Pharma, he was the CMC Head and SVP of Pharmaceutical Sciences in Ascentage Pharma. He previously worked at Shanghai R&D Center of Wisdom Pharma as VP Director. 

Dr. Wen obtained his Ph.D in Organic Chemistry from Shanghai Institute of Organic Chemistry of CAS and completed his Postdoctoral training in the University of Tokyo. He is the author or co-author, and inventor or co-inventor, of more than 30 publications and patents.

Coco Cao is the VP of Ablaze Pharma, focusing on overall quality management.

Mrs. Cao has over 20 years of experience in pharmaceutical industry, covering drug development, quality management, materials management, procurement management and so on.

Prior to Ablaze Pharma, Mrs. Cao was the Director of Quality, Qualified Person and AVP of Quality at Ascentage Pharma from 2017 to 2022. During the 11 years in Cinkate Pharma from 2010 to 2017 and 2004 to 2009, she started from the role of Assistant Manager of Quality Management Department to Director of Quality, Qualified Person and VP of Quality and Purchasing. Prior to that, Mrs. Cao was designated as the QA Audit at Amerigen Pharma from 2009 to 2010 and Deputy Director of Pharmaceutical Formulation Department at Jiangsu Wuzhong Pharma from 2002 to 2004. Mrs. Cao is very experienced in material management, procurement management and GMP quality management of innovative drugs, from research stage to the commercialization stage. She has led projects of new GMP facility’s building-up and the establishment of quality system, as well as participations in China GMP certifications, PAI inspection for new drug and FDA inspections, with profound experience in the overall quality management of large volume parenteral solution, small volume parenteral solution, oral solution, oral solid dosage form and API.

Mrs. Cao owned 1 invention patent issued by P.R.C. and received her BS Degree in Chinese Medicine of China Pharmaceutical University.

Dr. Zheng Song is the AVP of Ablaze Pharma，focusing on Pre-Clinical Development. She is a highly accomplished professional with over 16 years of experience in drug nonclinical strategy design, study conduction, and data interpretation. As a certified DABT (American Board of Toxicology) and DCST (Diplomat of Chinese Society of Toxicology), she possesses an extensive understanding of preclinical development.

Prior to joining Ablaze, Dr. Zheng Song served as Preclinical Development Head, Executive Director, at Elpiscience Biopharma, Ltd for five years. During this time, she led the preclinical development strategy design and study conduction for seven innovative antibodies to support their first-in-human clinical trials in China, the United States, and Australia. From 2007 to 2018, Dr. Zheng Song held the positions of Department Head and Project Leader at Shanghai InnoStar Bio-tech Co., Ltd. During her tenure, she led teams in completing over 60 preclinical safety evaluation projects for new candidate drugs across various therapy areas and mechanisms of action, achieving successful regulatory approvals from the FDA, NMPA, and Australia IND.

Dr. Zheng Song obtained her PhD degree from the Shanghai Institute of Pharmaceutical Industry after graduating from China Pharmaceutical University.